Business Context and Reporting Period
Company: AYTU BIOPHARMA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Event: Termination of a Material Definitive Agreement with Lannett Company, Inc.
Key Financial Metrics
Revenue: Net revenue from Metadate CD® for the quarter ended March 31, 2026, was $49,000.
Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
- Agreement Termination: On June 23, 2026, the Company and Lannett mutually terminated the exclusive license agreement (the "Metadate Agreement") originally entered into on May 11, 2022, and amended in 2023 and 2025.
- Post-Termination Rights: The Company retains the right to sell and distribute existing inventory at its sole discretion.
- Ongoing Obligations: The Company must continue to provide royalty reports and pay royalties until sales of existing inventory cease.
Guidance, Outlook, and Risks
Management Commentary: The termination was mutual. The full text of the Termination Agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ended June 30, 2026.
Risks and Contingencies: Future revenue from Metadate CD® is limited to the sale of existing inventory. The filing does not provide specific forward-looking guidance or discuss other risks beyond the termination event.
Investor Verification Checklist
- Verify the exact volume of existing Metadate CD® inventory available for sale post-termination.
- Review the full Termination Agreement (to be filed in the 2026 Form 10-K) for specific royalty rates and survival clauses.
- Assess the impact of the $49,000 quarterly revenue loss on the Company's overall financial position once inventory is depleted.
- Confirm if the termination affects any other pending regulatory or commercial agreements with Lannett.